Dandy-Walker variant in an infant prenatally exposed to antiretroviral medication [7]

South African Medical Journal

Volumn 97, Issue 10 I, 2007, Pages 947-948

  Urban, Mike F ^a   Chersich, M F ^b,c  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b International Centre for Reproductive Health Kenya   (Kenya)

^c GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; ETHAMBUTOL; ISONIAZID; LAMIVUDINE; NEVIRAPINE; PYRAZINAMIDE; RIFAMPICIN; STAVUDINE;

ADULT; AMNIOCENTESIS; BRAIN VENTRICLE DILATATION; CASE REPORT; DANDY WALKER SYNDROME; ECHOGRAPHY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFANT; KARYOTYPE; LETTER; MALE; PRENATAL DIAGNOSIS; PRENATAL DRUG EXPOSURE; TERATOGENICITY; TUBERCULOSIS;

ADULT; ANTI-RETROVIRAL AGENTS; DANDY-WALKER SYNDROME; FEMALE; HEART VENTRICLES; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; LAMIVUDINE; MALE; NEVIRAPINE; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; STAVUDINE; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 35648946838     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (13)

1. Ten Donkelaar HJ, Lammens M, Wesseling P, Thijssen HOM and Remer WO. Development and developmental disorders of the human cerebellum. J Neurol 2003; 250: 1026-1036.
2. Ecker JL, Shipp TD, Bromley B, Benacerraf B. The sonographic diagnosis of Dandy-Walker and Dandy-Walker variant: associated findings and outcomes. Prenat Diagn 2000; 20(4): 328-332.
3. Committee on the Assessment of the US Drug Safety System. Baciu A, Stratton K, Burke SP, eds. The Future of Drug Safety: Promoting and Protecting the Health of the Public. http://www.nap.edu/catalog/ 11750.html (last accessed 2 January 2007).
4. Psaty BM, Burke SP. Protecting the health of the public - Institute of Medicine regulations on drug safety. N Engl J Med 2006; 355(17): 1753-1755.
5. Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral pregnancy registry international interim report for 1 January 1989 through 31 January 2006. Wilmington, NC: Registry Coordinating Center; 2006. http://www.APRegistry.com (last accessed 2 March 2007).
6. Jungmann EM, Mercey D, DeRuiter A, et al. Is first trimester exposure to the combination of antiretroviral therapy and folate antagonists a risk factor for congenital abnormalities,? Ser Transm Infect 2001; 77(6): 441-443.
7. May PA, Gossage JP, White-Country M, et al. Alcohol consumption and other maternal risk factors for fetal alcohol syndrome among three distinct samples of women before, during, and after pregnancy: the risk is relative. Am J Med Genet 2004,127C: 10-20.
8. Mofenson LM. Efavirenz reclassified as FDA pregnancy category D. AIDS Clin Care 2005; 17(2): 17.
9. Nightingale SL. From the Food and Drug Administration. JAMA 1998; 280(17):1472.
10. De Santis M, Carducci B, De Santis L, Cavaliere AF, Straface G. Periconceptional exposure to efavirenz and neural tube defects. Arch Intern Med 2002; 162(3): 355.
11. Fundaro C, Genovese C, Rendeli C, Tamburrini E, Salvaggio E. Myelomeningocele in a child with intrauterine exposure to efavirenz. AIDS 2002; 16(2): 299-300.
12. Saitoh A, Hull AD, Franklin F, Spector SA. Myelomeningocele in an infant with intrauterine exposure to efavirenz. J Perinatol 2005; 25(8): 555-556.
13. World Health Organization. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants in resource-limited settings: towards universal access. 2006. http://www.who.int/hiv/pub/ guidelines/pmtct/en/index.html http://www.who.int/hiv/pub/guidelines/ pmtct/en/index.html (last accessed 5 September 2007).